At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
With at least 24 inherited retinal disease (IRD) clinical trials ongoing in the United States, and additional studies of stem cell therapy in several IRD indications, hope is on the horizon for many patients.
In “modified monovision”, which can be achieved with a new IOL, one eye predominantly manages distance vision and the other near vision—as with standard monovision—but the extended depth of field provides a degree of intermediate vision that is independent of spectacles.
Poorly focused YAG shots lead irrevocably to a permanent defect in the IOL material and thus to possible effects on the quality of vision with straylight or glare. In a recent study, the differing amounts of damage that Nd:YAG causes in a range of hydrophilic and hydrophobic acrylic lens materials was assessed.